47 results match your criteria: "Central Clinical Trials Unit[Affiliation]"
Clin Exp Allergy
December 2024
Department of Allergy and Clinical Immunology, Clínica Universidad de Navarra, Pamplona, Spain.
Med Clin (Barc)
September 2024
Department of Dermatology, University Clinic of Navarra, Pamplona, Spain. Electronic address:
Eur J Anaesthesiol
June 2024
From the Department of Anaesthesia & Perioperative Medicine, Grupo Quirón - Policlínica Guipúzcoa, San Sebastián (DN), Department of Neurology, Clínica San Miguel, Pamplona (MM-F), Research Support Service, Central Clinical Trials Unit, Clínica Universidad de Navarra, Pamplona (JMN-C), Department of Anesthesiology & Critical Care Medicine, Clínica Universidad de Navarra, Pamplona, Spain (MV).
Br J Anaesth
September 2023
Department of Anaesthesia and Critical Care, Clínica Universidad de Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, 31080, Pamplona, Spain.
Background: Sugammadex has been associated with increases in the bispectral index (BIS). We evaluated the effects of sugammadex administration on quantitative electroencephalographic (EEG) and electromyographic (EMG) measures.
Methods: We performed a prospective observational study of adult male patients undergoing robot-assisted radical prostatectomy.
Front Med (Lausanne)
October 2022
Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.
Background: To better understand the patient's heterogeneity in fatty liver disease (FLD), metabolic dysfunction-associated fatty liver disease (MAFLD) was proposed by international experts as a new nomenclature for nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the cardiovascular risk, assessed through coronary artery calcium (CAC) and epicardial adipose tissue (EAT), of patients without FLD and patients with FLD and its different subtypes.
Methods: Cross sectional study of 370 patients.
Int J Mol Sci
August 2022
Department of Nuclear Medicine, Clinica Universidad de Navarra, CCUN Applied Medical Research, Instituto de Investigación Sanitaria de Navarra, 31008 Pamplona, Spain.
Multiple myeloma (MM) is the second most common haematological malignancy and remains incurable despite therapeutic advances. F-FDG (FDG) PET/CT is a relevant tool MM for staging and it is the reference imaging technique for treatment evaluation. However, it has limitations, and investigation of other PET tracers is required.
View Article and Find Full Text PDFSurg Today
February 2023
Research Support Service, Central Clinical Trials Unit, Clínica Universidad de Navarra, Pamplona, Spain.
Wrong surgery (wrong-site, wrong-procedure, or wrong-patient surgery) is among the most feared patient safety problems in hospitals. We aimed to evaluate associations between numeric assessment of risk assigned to wrong surgery with that of other healthcare quality and patient safety challenges. This nationwide study collected information from healthcare quality experts in charge of a clinical quality and/or patient safety department in general hospitals of ≥ 150 beds in Spain.
View Article and Find Full Text PDFAllergy
January 2023
Department of Allergy and Clinical Immunology, Clínica Universidad de Navarra, Pamplona, Spain.
N Engl J Med
June 2022
From the Health Research Institute of Navarra (J.G.P.-L., M.G.-M., S.L., A.P.-G., M.G.-H., M.Z., L.M., N.M.-V., M.P., V.L., S.H.-S., I.T., B.T., R.H.-A., M.V., C.A., S.T., M.M.A.), the Program in Solid Tumors (J.G.P.-L., M.G.-M., S.L., A.P.-G., M.G.-H., M.Z., L.M., N.M.-V., M.P., V.L., B.T., S.T., M.M.A.), the Program in Immunology (S.H.-S.), and the Program in Gene Therapy and Regulation of Gene Expression (R.H.-A.), Foundation for the Applied Medical Research, the Departments of Neurology (J.G.P.-L., I.E.V.), Pediatrics (M.G.-M., S.L., A.P.-G., M.G.-H., M.Z., L.M., N.M.-V., M.P., V.L., M.M.A.), Pathology (M.V., C.A.), and Neurosurgery (S.T.) and the Division of Biostatistics, Research Support Service, Central Clinical Trials Unit (J.M.N.-C.), Clínica Universidad de Navarra, the Service of Pediatric Hemato-Oncology, Hospital Universitario de Navarra (M.O.L.), Center for Applied Medical Research (CIMA) LAB Diagnostics, University of Navarra and Healthcare Research Institute of Navarra (G.A.-A.), and the Bioinformatics Platform, CIMA, University of Navarra (I.T.), Pamplona, the Department of Pediatric Oncology, Biocruces Bizkaia Health Research Institute, Barakaldo (I.A.), the Pediatric Department, Faculty of Medicine and Nursing, University of the Basque Country, Leioa (I.A.), the Department of Pediatric Oncology, Montepríncipe Hospital (B.L.-I.), the Department of Neurosurgery, Quirón Hospitals (R.D.-V., S.T.), and Centro de Investigación Biomédica en Red de Cáncer (M.V.), Madrid, the Department of Pediatric Oncology, Neuro-Oncology Unit, Hospital Sant Joan de Deu, Barcelona (O.C.), and the Department of Pathology, University Hospital Virgen Macarena and School of Medicine, University of Seville, Seville (M.Á.I.) - all in Spain; DNAtrix, Carlsbad, CA (J.D., B.E., J.R.); the Division of Molecular Pathology, Institute of Cancer Research, London (C.J.); the Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (G.D., C.R.-M., H.S., E.H., J.L.); and the Departments of Neuro-Oncology (J.F., C.G.-M.) and Neurosurgery (F.F.L.), University of Texas M.D. Anderson Cancer Center, Houston.
J Investig Allergol Clin Immunol
April 2023
Research Support Service, Central Clinical Trials Unit, Clínica Universidad de Navarra, Pamplona, Spain.
Sci Rep
April 2022
Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pio XII, 36, 31008, Pamplona, Spain.
Non-alcoholic fatty liver disease (NAFLD) is associated with cardiovascular disease morbimortality. However, it is not clear if NAFLD staging may help identify early or subclinical markers of cardiovascular disease. We aimed to evaluate the association of liver stiffness and serum markers of liver fibrosis with epicardial adipose tissue (EAT) and coronary artery calcium (CAC) in an observational cross-sectional study of 49 NAFLD patients that were seen at Clínica Universidad de Navarra (Spain) between 2009 and 2019.
View Article and Find Full Text PDFJ Dtsch Dermatol Ges
January 2022
Department of Dermatology, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spanien.
Br J Anaesth
March 2022
Research Support Service, Central Clinical Trials Unit, Clínica Universidad de Navarra, Pamplona, Spain; Institute of Data Science and Artificial Intelligence, University of Navarra, Pamplona, Spain. Electronic address:
J Dtsch Dermatol Ges
January 2022
Department of Dermatology, University Clinic of Navarra, School of Medicine, University of Navarra, Pamplona, Spain.
J Neurosurg Anesthesiol
January 2023
Research Support Service, Central Clinical Trials Unit, Clínica Universidad de Navarra, University of Navarra.
Background: The identification of factors associated with perioperative red blood cell (RBC) transfusion provides an opportunity to optimize the patient and surgical plan, and to guide perioperative crossmatch and RBC orders. We examined the association among potential bleeding risk factors and RBC requirements to develop a novel predictive model for RBC transfusion in patients undergoing brain tumor surgery.
Methods: This retrospective study included 696 adults who underwent brain tumor surgery between 2008 and 2018.
Background: During magnetic resonance-guided focused ultrasound for essential or parkinsonian tremor, adverse events (headache, nausea/vomiting, or anxiety) may alter the outcome of the procedure despite being mostly transient and mild.
Objectives: Our aim was to analyze the relationship between demographic, procedural, and anesthetic characteristics with magnetic resonance/ultrasound-related events.
Methods: This was a retrospective study at the Clinica Universidad de Navarra of patients undergoing thalamotomy with magnetic resonance-guided focused ultrasound between September 2018 and October 2019.
ERJ Open Res
April 2021
Pulmonary Medicine, Clínica Universidad de Navarra, Pamplona, Spain.
Br J Anaesth
August 2021
Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; Clinical Neurophysiology Section, Clínica Universidad de Navarra, Pamplona, Spain.
Background: Dexmedetomidine is frequently used for sedation during deep brain stimulator implantation in patients with Parkinson's disease, but its effect on subthalamic nucleus activity is not well known. The aim of this study was to quantify the effect of increasing doses of dexmedetomidine in this population.
Methods: Controlled clinical trial assessing changes in subthalamic activity with increasing doses of dexmedetomidine (from 0.
J Adv Nurs
July 2021
Department of Business, School of Economics and Business, University of Navarra, Pamplona, Spain.
Aims: To identify and prioritize the root causes of adverse drug events (ADEs) in hospitals and to assess the ability of artificial intelligence (AI) capabilities to prevent ADEs.
Design: A mixed method design was used.
Methods: A cross-sectional study for hospitals in Spain was carried out between February and April 2019 to identify and prioritize the root causes of ADEs.
J Neurosurg Anesthesiol
April 2022
Research Support Service, Central Clinical Trials Unit, Clínica Universidad de Navarra, University of Navarra.
J Transl Med
September 2020
Cell Therapy Area, Clínica Universidad de Navarra, 36 Pío XII Avenue, 31008, Pamplona, Spain.
Background: Mesenchymal stromal cells are a safe and promising option to treat knee osteoarthritis as previously demonstrated in different clinical trials. However, their efficacy, optimal dose and addition of adjuvants must be determined. Here, we evaluated the clinical effects of a dose of 100 × 10 bone marrow mesenchymal stromal cells (BM-MSCs) in combination with Platelet Rich Plasma (PRGF®) as adjuvant in a randomized clinical trial.
View Article and Find Full Text PDFNeurooncol Adv
January 2020
Health Research Institute of Navarra (IDISNA), Pamplona, Spain.
Background: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Circulating biomarkers may assist in the processes of differential diagnosis and response assessment. GBM cells release extracellular vesicles containing a subset of proteins and nucleic acids.
View Article and Find Full Text PDFBr J Haematol
June 2020
Cell Therapy Area and Department of Hematology, Clínica Universitaria de Navarra, Pamplona, Navarra, Spain.
Anti-cluster of differentiation 20 (CD20) monoclonal antibodies (mAbs) have shown promise in follicular lymphoma (FL) as post-induction therapy, by enhancing antibody-dependent cellular cytotoxicity (ADCC). However, cytotoxic cells are reduced after this treatment. We hypothesised that ex vivo expanded lymphokine-activated killer (LAK) cells administered to FL-remission patients are safe and improve anti-CD20 efficacy.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
July 2020
Department of Dermatology, Clínica Universidad de Navarra, Pamplona, Spain.
Background: Organ transplant recipients (OTR) have a higher risk of actinic keratosis (AK) and keratinocyte carcinomas (KC). There are no clinical trials assessing the effectiveness of daylight photodynamic therapy (DPDT) to prevent new AK and KC in OTR.
Objectives: To determine whether repeated treatments of field cancerization with DPDT are effective in preventing new AK and KC in OTR.